CN103504291A - 一种防治糖尿病和心脑血管病的饮料 - Google Patents
一种防治糖尿病和心脑血管病的饮料 Download PDFInfo
- Publication number
- CN103504291A CN103504291A CN201210232577.6A CN201210232577A CN103504291A CN 103504291 A CN103504291 A CN 103504291A CN 201210232577 A CN201210232577 A CN 201210232577A CN 103504291 A CN103504291 A CN 103504291A
- Authority
- CN
- China
- Prior art keywords
- beverage
- cerebrovascular diseases
- cardia
- preventing
- treating diabetes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000013361 beverage Nutrition 0.000 title claims abstract description 28
- 208000026106 cerebrovascular disease Diseases 0.000 title claims abstract description 16
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 14
- 239000000843 powder Substances 0.000 claims abstract description 14
- 244000228451 Stevia rebaudiana Species 0.000 claims abstract description 11
- 235000006092 Stevia rebaudiana Nutrition 0.000 claims abstract description 11
- 244000269722 Thea sinensis Species 0.000 claims abstract description 11
- 235000007164 Oryza sativa Nutrition 0.000 claims abstract description 10
- 235000009566 rice Nutrition 0.000 claims abstract description 10
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 15
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 13
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 11
- 229920001202 Inulin Polymers 0.000 claims description 9
- 241000209094 Oryza Species 0.000 claims description 9
- 229940029339 inulin Drugs 0.000 claims description 9
- 230000036541 health Effects 0.000 abstract description 6
- 230000002265 prevention Effects 0.000 abstract description 6
- 235000005911 diet Nutrition 0.000 abstract description 5
- 230000037213 diet Effects 0.000 abstract description 5
- 239000003814 drug Substances 0.000 abstract description 4
- 230000000694 effects Effects 0.000 abstract description 4
- 206010020772 Hypertension Diseases 0.000 abstract description 3
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract description 2
- 230000002490 cerebral effect Effects 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract description 2
- 210000001835 viscera Anatomy 0.000 abstract description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 240000007594 Oryza sativa Species 0.000 abstract 1
- 201000001421 hyperglycemia Diseases 0.000 abstract 1
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 230000001476 alcoholic effect Effects 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 208000004930 Fatty Liver Diseases 0.000 description 2
- 206010019708 Hepatic steatosis Diseases 0.000 description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 235000021329 brown rice Nutrition 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 208000010706 fatty liver disease Diseases 0.000 description 2
- 230000036449 good health Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 208000001280 Prediabetic State Diseases 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000002605 anti-dotal effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 230000001603 reducing effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 239000002893 slag Substances 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F3/00—Tea; Tea substitutes; Preparations thereof
- A23F3/34—Tea substitutes, e.g. matè; Extracts or infusions thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种防治糖尿病和心脑血管病的饮料,主要通过日常饮食方式从根源上对高血压、高血糖、高血脂和心脑血管病患者进行积极防治和保健;其特征在于把甜叶菊粉、糙米粉按科学比例配方,既可以用袋装茶也可以用瓶装饮料的形式体现实施;通过饮料这种大众化的载体,有效避免了药物对代谢综合征患者内脏器官的损害,该种饮料不仅口感好,还具有多种防治和保健功效,并且适应性广,推广应用价值高,维护人体心脑血管健康效果好的特点。
Description
所属技术领域
本发明涉及日常饮料类产品中的一种,包括含有酒精成份的饮料,主要通过日常饮食方式,从根源上对糖尿病和心脑血管病进行积极防治和保健。
背景技术
由于目前人们生活水平的大幅度提高和生活节奏越来越快,以及应激因素的无处不在,使人们罹患糖尿病和心脑血管病的因素也越来越多。据最新统计资料表明,我国目前有已被确诊为糖尿病的患者为0.924亿人,前期糖尿病患者为每16人中就有1人,很多患者因服药无效而被动地选择注射胰岛素疗法,而在1亿多人的心血管疾病患者中,有很多患者由于无奈而选择支架和搭桥术。
心脑血管疾病危害人类健康极为凶险,被称为“第一杀手”。在我国每年新发生的脑卒中病例为300万人,心肌梗死为60万人,心脑血管病死亡人数约260万人,平均每小时死亡300人。因此,对于糖尿病和心脑血管疾病,无论是从经济角度、家庭角度,还是从健康角度来讲,唯有预防才是万全之策,高明之举。早一日预防,早一日安心。因为预防胜于治疗,并能减少一半的死亡。
发明内容
结合目前糖尿病和心脑血管病在我国的猖獗和泛滥成灾之现状,与其消极被动地长期服用相关药物或者每天定量注射胰岛素,不如积极主动地通过日常饮食的方式给人体补充足够的健康元素,把复杂的事情简单化,从而实现有效维护人体健康的目的。
本发明的目的就是针对已有技术中存在的问题,设计提供一种集降血压、降血糖、降血脂、预防心脑血管疾病、抗衰老等多功能于一体的保健型饮料,包括含有酒精成份的饮料,达到在饮用一种饮料时即具有多种防治和保健功效,并且适应性广,推广应用价值高,人们喜饮爱用,主要通过日常饮食方式达到从根源上对糖尿病、心脑血管病、肥胖症、脂肪肝、高血压、高血脂、高胆固醇血症等患者的防治和保健效果好的目的。
本发明的基本设计是,一种防治糖尿病和心脑血管病的饮料,包括含有酒精成份的饮料,如各种酒类产品,其特征在于:把甜叶菊叶茎部分和炒熟后的糙米分别研成粉末状,按科学比例配方,装入包装袋内,以袋装茶的形式体现实施,袋装茶配方比例为:甜叶菊粉1微克~50克:糙米粉1微克~50克;袋装茶配方同饮料本体的配方比例为:甜叶菊粉1微克~50克、糙米粉1微克~50克:饮料本体1公斤。然后按照该饮料本体固有的生产工艺流程和制作方法加工而成,以瓶装饮料的形式体现实施。
本发明的有益效果是:通过饮料这种大众化的载体,用既经济又简单的方式给人体补充健康元素,不但能够免除糖尿病患者每天注射胰岛素的皮肉之苦,而且可以有效避免药物对代谢综合征患者内脏器官的损害;该种饮料不仅具有多种防治和保健功效,并且适应性广,推广应用价值高,维护人体心脑血管健康效果好的特点,而且还具有通过日常饮食方式轻松有效地从根源上对糖尿病、心脑血管病、肥胖症、脂肪肝、高血压、高血脂、高胆固醇血症及抗衰老的防治和保健效果好的特点。
图1是包装袋或容器及装置其内的饮料本体总体结构透视图。
图中标号说明:
1、包装袋或容器;2、甜叶菊粉;3、糙米粉;4、饮料本体。
具体实施方式
下面结合附图对本发明最佳实施方案进行详细描述。本发明的基本设计是,一种防治糖尿病和心脑血管病的饮料,其特征在于把鲜甜叶菊采集清洗干净后烘干并研成粉末状即甜叶菊粉2,再把糙米炒熟后研成粉末状即糙米粉3,然后把这两种成份按科学比例配方并以袋装茶的形式体现实施,袋装茶配方比例为:甜叶菊粉2 1微克~50克:糙米粉3 1微克~50克;而该配方同包括含有酒精成分在内的饮料本体4的配方比例为:甜叶菊粉21微克~50克、糙米粉3 1微克~50克:饮料本体4 1公斤。
上述配方既可以用袋装茶的形式体现实施也可以将该配方中的两种成分添加入包括含有酒精成份在内的饮料本体4中,搅拌均匀、浸泡、沉淀、去渣和过滤后装瓶,以瓶装的形式体现实施。然后按照袋装茶或者瓶装饮料本体4固有的生产工艺流程和制作方法加工而成。
在使用时,先把袋装茶放入茶杯或茶壶中,倒入热开水浸泡几分钟后即可饮用;而瓶装饮料本体4开盖后倒入杯中随饮即可。
Claims (1)
1.一种防治糖尿病和心脑血管病的饮料,其特征在于:把甜叶菊粉(2)、糙米粉(3)按科学比例配方配制而成,袋装茶配方比例为:甜叶菊粉(2)1微克~50克:糙米粉(3)1微克~50克;袋装茶配方同饮料本体(4)的配方比例为:甜叶菊粉(2)1微克~50克、糙米粉(3)1微克~50克:饮料本体(4)1公斤。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210232577.6A CN103504291A (zh) | 2012-06-26 | 2012-06-26 | 一种防治糖尿病和心脑血管病的饮料 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210232577.6A CN103504291A (zh) | 2012-06-26 | 2012-06-26 | 一种防治糖尿病和心脑血管病的饮料 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN103504291A true CN103504291A (zh) | 2014-01-15 |
Family
ID=49888147
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210232577.6A Pending CN103504291A (zh) | 2012-06-26 | 2012-06-26 | 一种防治糖尿病和心脑血管病的饮料 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103504291A (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1101229A (zh) * | 1993-10-08 | 1995-04-12 | 彭子生 | 强身营养快餐米粉 |
CN1123097A (zh) * | 1994-11-23 | 1996-05-29 | 淮安市神农保健食品公司 | “降糖糊”及其生产工艺 |
CN101449810A (zh) * | 2007-11-28 | 2009-06-10 | 天津市中英保健食品有限公司 | 强身营养快餐米粉 |
-
2012
- 2012-06-26 CN CN201210232577.6A patent/CN103504291A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1101229A (zh) * | 1993-10-08 | 1995-04-12 | 彭子生 | 强身营养快餐米粉 |
CN1123097A (zh) * | 1994-11-23 | 1996-05-29 | 淮安市神农保健食品公司 | “降糖糊”及其生产工艺 |
CN101449810A (zh) * | 2007-11-28 | 2009-06-10 | 天津市中英保健食品有限公司 | 强身营养快餐米粉 |
Non-Patent Citations (2)
Title |
---|
司玉芹 等: "糖尿病患者的保健茶--甜叶菊茶", 《中国果蔬》 * |
杜萍: "《健康一生的科学方法》", 31 May 2010, 中国编译出版社 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101716182B (zh) | 含盐酸二甲双胍和维生素b12的组合药物 | |
CN102132754A (zh) | 一种减肥降脂茶及其制备方法 | |
CN104642606A (zh) | 速溶银杏茶及其制备方法 | |
CN101099526B (zh) | 人参花保健茶饮料及其制备方法 | |
CN101792703B (zh) | 一种滇橄榄茶酒及其制备方法 | |
CN103190494A (zh) | 富硒黄芪保健茶及其茶包 | |
CN105596576A (zh) | 一种具有降血脂作用的袋泡茶 | |
CN103536904B (zh) | Metrnl蛋白在制备降血糖药物方面的应用 | |
KR20160141027A (ko) | 아위버섯 물 추출물을 유효성분으로 함유하는 대사성질환의 예방 및 치료용 약학적 조성물 또는 건강기능성식품 | |
CN107648287B (zh) | 一种雏凤膏软膏及其在制备治疗产妇***皲裂药物中的应用 | |
CN107223830A (zh) | 一种制备预防和缓解痛风功能饮料的方法 | |
CN103504291A (zh) | 一种防治糖尿病和心脑血管病的饮料 | |
CN102008103B (zh) | 一种保健饮料及其制备方法 | |
CN104958309A (zh) | 芦丁在制备用于治疗肥胖及相关疾病的药物中的应用 | |
CN102697135A (zh) | 明目三降功能饮料 | |
CN103652059B (zh) | 袋泡药茶的配方及制备方法 | |
CN103783377B (zh) | 一种青稞保健粉及其制备方法 | |
CN106138115A (zh) | 中药材金蝉花的新用途 | |
CN102225110A (zh) | 一种配用白花蛇舌草的蜂胶酒及制法 | |
CN102166029A (zh) | 一种仙草多菌养生精功能饮料 | |
CN111298052A (zh) | 一种洽疗糖尿病的药品 | |
CN104256802A (zh) | 一种醒酒瓜蒌汁配方 | |
CN109198614A (zh) | 一种降低血糖食品的配方及其制备方法 | |
CN103504074A (zh) | 一种三高克星保健茶 | |
WO2007118368A1 (fr) | Thé pharmaceutique destiné à réduire la glycémie et procédé associé |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20140115 |